Paragon 28 Inc - FNA STOCK NEWS

Paragon 28, Inc. (NYSE: FNA) has launched the R3ACT™ Stabilization System, aimed at enhancing soft tissue healing for syndesmotic ankle injuries. This system is designed to address the complexities of stabilization throughout various healing phases. CEO Albert DaCosta emphasized that around 20% of ankle injuries necessitate implants for recovery, positioning the R3ACT™ as a valuable addition to their ankle fracture solutions. Paragon 28 specializes in the foot and ankle orthopedic market, focusing on innovative solutions to improve patient outcomes.

Paragon 28, Inc. (NYSE: FNA) announced it will release its Q1 2022 financial results after market close on May 9, 2022. A conference call will follow at 4:30 p.m. ET, and investors can access it by calling (844-200-6205) within the U.S. or (646-904-5544) internationally, using conference ID: 990038. CEO Albert DaCosta and CFO Steve Deitsch will also present at the Bank of America Healthcare Conference in Las Vegas on May 10, at 2:00 p.m. PT. Live webcasts will be available on the company’s website.

Paragon 28, Inc. (NYSE: FNA) has appointed Meghan Scanlon to its Board of Directors, enhancing its leadership team. With over 20 years in the medical device sector, Scanlon currently serves as senior vice president at Boston Scientific Corporation. She will also contribute to the Compensation and Quality, Technology and Regulatory Committees. Paragon 28 aims to improve outcomes for foot and ankle patients, focusing on innovative orthopedic solutions and procedural approaches.

Paragon 28, Inc. (NYSE: FNA), a premier medical device company focusing on foot and ankle orthopedics, announced presentations by CEO Albert DaCosta and CFO Steve Deitsch at the Canaccord Genuity Musculoskeletal Conference on March 22, 2022, and the Needham Healthcare Conference on April 11, 2022. Both events will be webcast live, with the Canaccord chat at 12:30pm ET and the Needham chat at 11:00am ET. Archived recordings will be available on the company’s investor relations website.

Paragon 28 (NYSE: FNA) reported Q4 2021 net revenue of $42.8 million, a 22% increase year-over-year, and total revenue of $147.5 million for 2021, reflecting 33% growth. The gross margin improved to 81.7% from 72.3% in the prior year, attributed to higher margin product sales. However, operating expenses surged to $40.0 million, leading to a net loss of $6.2 million. The company expects net revenue for 2022 to be between $167.0 million and $171.0 million, indicating growth of 13% to 16%, despite potential COVID-19 challenges.

Paragon 28, Inc. (NYSE: FNA), a medical device leader in the foot and ankle orthopedic market, will announce its Q4 and full year 2021 financial results on March 8, 2022, after market close. A conference call will follow at 4:30 p.m. ET, accessible via phone or through a webcast on the company’s website. Investors can dial (844-200-6205) domestically or (929-526-1599) internationally using conference ID: 902702. The audio will be archived for 90 days post-event.

Paragon 28, Inc. (NYSE: FNA) has announced the acquisition of Disior Oy, a software company specializing in 3D analytics for foot and ankle surgery. The $18 million upfront payment, with potential future payments of up to $8 million, aims to enhance Paragon 28's SMART 28™ ecosystem. This integration will improve pre-operative planning and surgical outcomes for foot and ankle surgeons, aligning with Paragon 28's mission to modernize surgery and enhance patient care.

Paragon 28, Inc. (NYSE: FNA) announced its preliminary unaudited revenue for Q4 and the full year ended December 31, 2021. Q4 revenue is projected between $42.3 million and $42.7 million, marking a growth of approximately 20.7% to 21.8% year-over-year. For the entire year, expected revenue is between $147.0 million and $147.4 million, reflecting a growth of 32.4% to 32.8% compared to 2020. The company attributes this growth to its innovative foot and ankle portfolio and recent IPO, which has strengthened its financial position.

Paragon 28, Inc. (NYSE: FNA) announced FDA 501(k) marketing clearance for its R3ACT™ Stabilization System, set for commercial launch in early 2022. This product enhances Paragon 28's existing portfolio aimed at ankle fractures and soft tissue stabilization. CEO Albert DaCosta highlighted the product's innovative design, which meets complex needs in syndesmotic stabilization and adapts to healing phases of soft tissues. This new addition complements current offerings, including the Gorilla® and Mini-Monster® systems, strengthening the company's position in the orthopedic market.